Insulet (NASDAQ:PODD) Shares Gap Up – Still a Buy?

Insulet Corporation (NASDAQ:PODD)’s stock price gapped up before the market opened on Tuesday . The stock had previously closed at $138.97, but opened at $143.00. Insulet shares last traded at $144.3340, with a volume of 122,179 shares traded.

Wall Street Analyst Weigh In

Several research analysts have recently issued reports on PODD shares. Oppenheimer reduced their target price on shares of Insulet from $300.00 to $210.00 and set an “outperform” rating on the stock in a research note on Thursday, May 7th. Wells Fargo & Company dropped their price target on shares of Insulet from $360.00 to $255.00 and set an “overweight” rating for the company in a research note on Wednesday, May 6th. Wall Street Zen upgraded shares of Insulet from a “buy” rating to a “strong-buy” rating in a report on Saturday, May 9th. Benchmark reaffirmed a “buy” rating on shares of Insulet in a research note on Wednesday, May 27th. Finally, Leerink Partners lowered their target price on shares of Insulet from $360.00 to $247.00 in a report on Thursday, May 7th. Twenty-two investment analysts have rated the stock with a Buy rating, five have assigned a Hold rating and one has issued a Sell rating to the company’s stock. Based on data from MarketBeat, the company currently has a consensus rating of “Moderate Buy” and an average price target of $238.67.

Insulet Price Performance

The company has a market capitalization of $9.97 billion, a price-to-earnings ratio of 33.51, a price-to-earnings-growth ratio of 1.15 and a beta of 1.13. The company has a 50-day moving average price of $162.97 and a 200-day moving average price of $224.47. The company has a debt-to-equity ratio of 0.71, a quick ratio of 1.81 and a current ratio of 2.49.

Insulet (NASDAQ:PODD) last announced its quarterly earnings results on Wednesday, May 6th. The medical instruments supplier reported $1.42 EPS for the quarter, beating analysts’ consensus estimates of $1.19 by $0.23. Insulet had a return on equity of 26.87% and a net margin of 10.44%.The company had revenue of $761.70 million during the quarter, compared to analysts’ expectations of $729.89 million. During the same period in the prior year, the business posted $1.02 EPS. Insulet’s revenue was up 33.9% on a year-over-year basis. Insulet has set its FY 2026 guidance at 6.210- EPS. On average, equities research analysts expect that Insulet Corporation will post 6.46 EPS for the current fiscal year.

Insider Activity

In other Insulet news, Director Timothy C. Stonesifer purchased 2,790 shares of the stock in a transaction on Wednesday, June 3rd. The stock was bought at an average cost of $143.51 per share, for a total transaction of $400,392.90. Following the completion of the acquisition, the director directly owned 9,041 shares of the company’s stock, valued at $1,297,473.91. The trade was a 44.63% increase in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available at the SEC website. 0.36% of the stock is owned by company insiders.

Institutional Trading of Insulet

Several hedge funds have recently bought and sold shares of the stock. Glenmede Investment Management LP lifted its stake in Insulet by 1.6% in the third quarter. Glenmede Investment Management LP now owns 2,292 shares of the medical instruments supplier’s stock valued at $708,000 after buying an additional 35 shares in the last quarter. Curi Capital LLC boosted its holdings in shares of Insulet by 0.8% in the second quarter. Curi Capital LLC now owns 4,346 shares of the medical instruments supplier’s stock valued at $1,365,000 after buying an additional 36 shares during the period. WINTON GROUP Ltd increased its position in shares of Insulet by 0.9% during the third quarter. WINTON GROUP Ltd now owns 4,086 shares of the medical instruments supplier’s stock worth $1,261,000 after acquiring an additional 37 shares in the last quarter. Great Lakes Advisors LLC increased its position in shares of Insulet by 1.5% during the fourth quarter. Great Lakes Advisors LLC now owns 2,784 shares of the medical instruments supplier’s stock worth $791,000 after acquiring an additional 40 shares in the last quarter. Finally, Camarda Financial Advisors LLC raised its holdings in shares of Insulet by 0.5% during the second quarter. Camarda Financial Advisors LLC now owns 7,332 shares of the medical instruments supplier’s stock worth $2,304,000 after acquiring an additional 40 shares during the period.

Insulet Company Profile

Insulet Corporation is a medical device company headquartered in Acton, Massachusetts, that develops, manufactures and sells insulin-delivery systems for people with diabetes. The company’s core business is the design and commercialization of its Omnipod family of tubeless, wearable insulin pumps and the consumable Pods that deliver insulin. Insulet’s products aim to simplify insulin delivery for people with type 1 diabetes and insulin-requiring type 2 diabetes by offering an alternative to traditional insulin pens and tethered pump systems.

The company’s product portfolio includes the Omnipod System line—disposable, waterproof Pods that adhere to the skin and deliver insulin—and the associated controllers and mobile applications used to program and monitor insulin delivery.